December 2009

November/December 2009 Supplement

Articles

CHIEF MEDICAL EDITOR’S PAGE

RESEARCH RESULTS

  • Nerve Growth Factor and Glaucoma

    The overall disappointing results of neuroprotective studies thus far should not halt promising research.

    By Michael Belkin, MA, MD

SURGICAL ROUNDS FROM THE HAMILTON GLAUCOMA CENTER

  • Bleb Dysesthesia

    By Eric H. Leung, MD, MS; Christopher Rodarte, MD; Felipe A. Medeiros, MD, PHD; and Robert N. Weinreb, MD

TECHNOLOGY TODAY

COVER STORY: END-STAGE GLAUCOMA

CHALLENGING CASES

PRACTICE POINTERS

  • Weathering the Economic Recession

    Glaucoma Today asked five physicians to share how they are managing their practices.

    By Brian Flowers, MD; George R. Reiss, MD; Adam C. Reynolds, MD; Michael H. Rotberg, MD; and George Shafranov, MD

INSIDE EYETUBE.NET

5 QUESTIONS

  • Janey L. Wiggs, MD, PhD

    Dr. Wiggs comments on the potential clinical applications as well as the challenges of genetic research in glaucoma.

View All News >
News
Letters

b class="red"A WORD ON BLEBS/bbremThe following reader/author exchange is in reference to an editorial by Richard A. Lewis, MD, and an article titled “Closing the Fornix-Based Flap” by Craig Marcus, MD, and Garry P. Cond... more >

News
TBI Introduces First Sterile Corneal Allograft

Tissue Bank International (Baltimore, MD) has announced the availability of the VisionGraft Sterile Cornea, a sterile corneal allograft for use in tectonic transplant procedures. It is ready to use at room temperature and has ... more >

News
ASICO Unveils New Glaucoma Surgical Tools

ASICO LLC (Westmont, IL) debuted its Neuhann USC Glaucoma Marker: AE-1529 and Kitahara Glaucoma Punch: AE-8304 at the 2009 AAO Annual Meeting in San Francisco. The Kitahara Glaucoma Punch’s 1.0-mm X 1.0-mm square 360° ti... more >

News
AR-12286 Rho-Kinase Inhibitor Achieves Positive Results

In a phase 2a study, a Rho-kinase (ROCK) inhibitor (AR- 12286; Aerie Pharmaceuticals, Inc., Bridgewater, NJ) produced a statistically significant decrease in IOP with q.d. and b.i.d. dosing. The study enrolled 88 patients with ... more >

TOP 5 ARTICLES FROM DECEMBER 2009